|
Market Closed -
Nasdaq
00:00:00 08/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 224.41 USD | +0.21% |
|
-9.05% | -43.57% |
| 03:38pm | RBC Lowers Price Target on Alnylam Pharmaceuticals to $345 From $350, Keeps Outperform Rating | MT |
| 09-17 | Alnylam Pharmaceuticals, Inc. - Special Call |
| Market Cap | 30.03B 26.83B 25.03B 22.74B 42.82B 2,905B 43.14B 301B 118B 1,477B 113B 110B 4,749B | P/E 2026 * |
33.7x | P/E 2027 * | 23.7x |
|---|---|---|---|---|---|
| Enterprise Value | 26.99B 24.12B 22.5B 20.44B 38.49B 2,611B 38.78B 270B 106B 1,328B 101B 99.15B 4,269B | EV / Sales 2026 * |
4.92x | EV / Sales 2027 * | 3.63x |
| Free-Float |
99.82% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ALNY | Delayed | |
CBOE
| ALNY | Real-time | |
|
Tradegate
| DUL | Real-time | |
|
Berne S.E.
| DUL | End-of-day quote | |
|
Xetra
| DUL | End-of-day quote | |
|
London S.E.
| 0HD2 | Delayed | |
|
Wiener Boerse
| ALNY | End-of-day quote | |
|
Boerse Muenchen
| DUL | Real-time | |
|
Deutsche Boerse AG
| DUL | Delayed | |
|
Börse Stuttgart
| DUL | Delayed | |
|
Borsa Italiana
| 1ALNY | End-of-day quote |
Last Transcript: Alnylam Pharmaceuticals, Inc.
| 1 day | +0.21% | ||
| 1 week | -9.05% | ||
| Current month | -9.05% | ||
| 1 month | -15.67% | ||
| 3 months | -30.22% | ||
| 6 months | -29.77% | ||
| Current year | -43.57% |
| 1 week | 215.46 |  | 231.36 |
| 1 month | 215.46 | | 261.98 |
| Current year | 197.81 | | 427.05 |
| 1 year | 197.81 | | 495.55 |
| 3 years | 141.98 | | 495.55 |
| 5 years | 117.58 | | 495.55 |
| 10 years | 31.38 | | 495.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 01/01/2022 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 58 | 13/08/2019 |
| Chief Tech/Sci/R&D Officer | - | 01/04/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 80 | 23/04/2012 |
Amy Schulman
CHM | Chairman | 65 | 05/01/2023 |
David Pyott
BRD | Director/Board Member | 72 | 18/12/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 02/10/26 | Sell | General Counsel | -1,758 | 0.0013% | ||
| 19/09/26 | Free | Chief Executive Officer | 107 | 0.0001% | ||
| 01/06/26 | Exercice | Director | 11,490 | 0.0086% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.21% | -9.05% | -51.17% | +26.84% | 30.03B | |
| +2.70% | +2.73% | +40.91% | +110.31% | 1,060B | |
| +1.44% | -2.38% | +36.83% | +63.95% | 623B | |
| +1.75% | +3.73% | +16.55% | +83.05% | 480B | |
| +0.60% | -1.73% | +62.98% | +37.46% | 352B | |
| -1.39% | +1.43% | +21.52% | +41.12% | 345B | |
| -1.05% | +0.37% | +11.27% | +34.46% | 274B | |
| -0.96% | -2.05% | -5.88% | +10.80% | 249B | |
| +2.60% | -2.00% | +39.77% | +54.44% | 223B | |
| +1.82% | -1.48% | +25.75% | +96.48% | 182B | |
| Average | -0.44% | -1.34% | +19.85% | +55.89% | 381.8B | |
| Weighted average by Cap. | -0.43% | -0.03% | +30.77% | +69.82% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.48B 4.9B 4.57B 4.15B 7.82B 530B 7.88B 54.91B 21.45B 270B 20.58B 20.13B 867B | 6.94B 6.2B 5.79B 5.26B 9.9B 672B 9.98B 69.57B 27.18B 342B 26.07B 25.51B 1,098B |
| Net income | 900M 804M 751M 682M 1.28B 87.1B 1.29B 9.02B 3.52B 44.3B 3.38B 3.31B 142B | 1.29B 1.15B 1.07B 974M 1.83B 124B 1.85B 12.88B 5.03B 63.27B 4.83B 4.72B 203B |
| Net Debt | -3.03B -2.71B -2.53B -2.3B -4.33B -294B -4.36B -30.4B -11.88B -149B -11.39B -11.15B -480B | -4.81B -4.29B -4.01B -3.64B -6.85B -465B -6.9B -48.13B -18.8B -236B -18.04B -17.65B -760B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/10/26 | $224.41 | +0.21% | 1,064,112 |
| 06/10/26 | $223.94 | +1.84% | 1,356,362 |
| 05/10/26 | $219.89 | +0.08% | 1,281,104 |
| 02/10/26 | $219.72 | -4.96% | 1,661,854 |
| 01/10/26 | $231.18 | -6.31% | 2,017,406 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALNY Stock
Select your edition
All financial news and data tailored to specific country editions
